|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cyclin D1 overexpression in esophageal cancer from southern China and its clinical significance.
|
16051426 |
2006 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer.
|
8415648 |
1993 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Among the down-regulated miRNAs in SCI, 21, 19 and 20 miRNAs were potentially associated with hematological, bladder and esophageal cancer, respectively, and three target genes (<i>TP53, CCND1 and KRAS</i>) were common to all three types of cancer.
|
31444279 |
2019 |
|
Esophageal Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Amplification of the cyclin D1 gene is a reliable prognostic factor and post-translational modification of this gene may play a functionally important role in development of primary esophageal cancer.
|
9458316 |
1998 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study.
|
14966901 |
2004 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
In CCND1 G870A polymorphism, the AA genotype was marginally associated with higher risk of esophageal cancer (OR 1.5, 95%CI=0.98-2.4, P=0.05).
|
17561354 |
2007 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In CCND1 G870A polymorphism, the AA genotype was marginally associated with higher risk of esophageal cancer (OR 1.5, 95%CI=0.98-2.4, P=0.05).
|
17561354 |
2007 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, S6 and S6 kinase 1 knockdown resulted in attenuation of viability by suppressing cyclin D1 expression in esophageal cancer cells.
|
22996377 |
2013 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Increased DNA content and heteroploid rate, accumulation of p53 protein, and over-expression of p21, telomerase and cyclin D1 proteins were early molecular events during the development of esophageal cancer.
|
14606066 |
2003 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer.
|
17912028 |
2007 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Ki67, p53, cyclin D1 and pRB expression may be useful biomarkers for assessing the risk of developing esophageal cancer.
|
16273238 |
2005 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Overexpression of cyclin D1 protein was identified in 37.5% of the specimens of esophageal tumors and 35% of gastric tumors, and overexpression of Her-2/neu protein in 12.5 and 7.5%, respectively.
|
16490596 |
2006 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Pin1 is a critical therapeutic and preventive target in esophageal cancer because of its positive regulation of β-catenin and cyclin D1.
|
28325828 |
2017 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF (18 eligible studies, n=1476, HR=1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n=1476, HR=1.82, 95% CI, 1.50-2.20), Ki-67 (3 eligible studies, n=308, HR=1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen (5 eligible studies, n=700, HR=1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma included COX-2 (2 eligible studies, n=235, HR=3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n=291, HR=2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n=858, HR=1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n=2851, HR=1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies, n=1382, HR=2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n=544, HR=0.91, 95% CI, 0.83-1.00).
|
24206575 |
2013 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Results suggest that TC21 mediates its effects via the PI3K-Akt pathway, NF-κB and cyclin D1, and enhances chemoresistance in esophageal cancer cells.
|
22919244 |
2012 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Taken together, our results suggest that the CCND1 G870A polymorphism might not be a potential candidate for predicting esophageal cancer risk.
|
23661400 |
2013 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The CCND1-EMS1 locus on human chromosome 11q13 is amplified in esophageal cancer, bladder tumors, and breast cancer.
|
12739008 |
2003 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The overall data suggest that CCND1 G870A variation might have an association with increased esophageal cancer susceptibility.
|
23020291 |
2012 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings suggested that CCND1 amplification and co-alternation of CCND1(+) /pRb(-) /ppRb(+) may play a crucial role in the prognostic evaluation of patients with esophageal cancer, and the patients with CCND1(+) /pRb(-) /ppRb(+) have the worst prognosis in all the patients.
|
22150974 |
2013 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These results suggest that cyclin D1 may play an important role in carcinogenesis and that cyclin D1 overexpression may be a useful prognostic factor in esophageal cancer.
|
7747810 |
1995 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
To determine whether cyclin D1 is subject to mutations that inhibit its nuclear export in human cancer, we have sequenced exon 5 of cyclin D1 in primary esophageal carcinoma samples and in cell lines derived from esophageal cancer.
|
16732330 |
2006 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To determine whether cyclin D1 is subject to mutations that inhibit its nuclear export in human cancer, we have sequenced exon 5 of cyclin D1 in primary esophageal carcinoma samples and in cell lines derived from esophageal cancer.
|
16732330 |
2006 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To elucidate the molecular functions of cyclin D1 on EMT phenotypes and esophageal cancer radiosensitivity, we treated the radioresistant esophageal cancer cells (KYSE-150R) and parental cells (KYSE-150) with cyclin D1 small interfering RNA (siRNA).
|
26561473 |
2016 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To further address the roles of cyclin D1 in growth control and tumorigenesis, we have overexpressed an antisense cyclin D1 cDNA construct, either constitutively or inducibly, in the HCE7 human esophageal cancer cell line in which cyclin D1 is amplified and expressed at high levels.
|
7630641 |
1995 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Upregulation of plasma miR-93-5p expression significantly increases the risk of esophageal cancer and is associated with poor prognosis. miR-93-5p transferred by exosomes promotes the proliferation of recipient esophageal cancer cells and affects the expression of PTEN and its downstream proteins p21 and cyclin D1.
|
29673440 |
2018 |